Tharimmune, Inc. | WebDisclosure

BRIEF

published on 08/20/2025 at 14:05, 3 months 15 days ago

Tharimmune révèle des résultats prometteurs de simulation pharmacocinétique pour le TH104

TH104 Tharimmune Contre-mesures Aux Opioïdes Simulation Pharmacocinétique Formulation Du Film Buccal
BRIEF

published on 08/20/2025 at 14:05, 3 months 15 days ago

Tharimmune Reveals Promising PK Simulation Results for TH104

TH104 Tharimmune Opioid Countermeasure Pharmacokinetic Simulation Buccal Film Formulation
PRESS RELEASE

published on 08/20/2025 at 14:00, 3 months 15 days ago

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
Tharimmune announces positive results from PK simulation analysis of TH104 buccal film formulation of nalmefene as prophylactic countermeasure for high-potency opioids exposure

TH104 Buccal Film Tharimmune Pharmacokinetic Simulation Prophylactic Countermeasure
BRIEF

published on 08/13/2025 at 14:06, 3 months 22 days ago

Tharimmune renforce son portefeuille de brevets pour le TH-104

FDA Brevets Tharimmune TH-104 Opioïdes
BRIEF

published on 08/13/2025 at 14:06, 3 months 22 days ago

Tharimmune Strengthens Patent Portfolio for TH-104

FDA Patents Tharimmune TH-104 Opioids
PRESS RELEASE

published on 08/13/2025 at 14:01, 3 months 22 days ago

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
Tharimmune, Inc. expands its intellectual property portfolio for TH-104, a transmucosal film, for broader indications with new patents. FDA positive feedback accelerates national security efforts

Tharimmune Inc. FDA Feedback Patents TH-104 Intellectual Property Portfolio
BRIEF

published on 08/05/2025 at 14:05, 3 months 30 days ago

Nancy Davis rejoint le conseil d'administration de Tharimmune

Conseil D'administration Tharimmune Dépendance Thérapies Nancy Davis
BRIEF

published on 08/05/2025 at 14:05, 3 months 30 days ago

Nancy Davis Joins Tharimmune Board of Directors

Board Of Directors Addiction Tharimmune Thérapies Nancy Davis
PRESS RELEASE

published on 08/05/2025 at 14:00, 3 months 30 days ago

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Tharimmune, Inc. appoints philanthropist Nancy Davis to Board of Directors, bringing patient advocacy expertise to advance innovative therapies for critical medical needs

Board Of Directors Tharimmune Inc. Patient Advocacy Clinical-stage Biotechnology Nancy Davis
BRIEF

published on 08/04/2025 at 14:05, 4 months ago

Tharimmune fait progresser des thérapies clés contre le fentanyl militarisé et l'inflammation

TH104 Tharimmune TH023 Fentanyl Administration D'anticorps Par Voie Orale

Published on 12/05/2025 at 02:35, 6 hours 41 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 46 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 8 hours 16 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 11 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 16 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

Published on 12/05/2025 at 09:05, 10 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 15 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 16 minutes ago

SPECTRIS PLC - Removal
Published on 12/05/2025 at 09:00, 16 minutes ago

Official List Notice
Published on 12/05/2025 at 09:00, 16 minutes ago

Petershill Partners plc - Removal

View all EQS

Published on 12/05/2025 at 08:45, 31 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 31 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 33 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 1 minute ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 16 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE

News